Bruker Corporation
BRKRHealthcareNASDAQMedical Devices · Last scanned May 29, 2026
Scan Results
Daily timeframeBruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. The $8.28B market capitalization puts BRKR squarely in mid-cap range for its industry. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Market Cap
$8.28B
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
22.50
EPS (TTM)
$-0.24
EPS (Fwd)
$2.42
ROE
-0.4%
ROA
2.7%
Cash
$133.4M
Total Debt
$1.70B
Free CF
$212.5M
52W Change
48.2%
Annual Financials
Cash vs Debt
The company holds $133.4M in cash, though total debt stands at $1.70B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $212.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -0.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.53B (2022) to $3.44B (2025), reflecting a 36% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing BRKR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.